Skip to main content
Unknown status

A Clinical Study With Tremelimumab as Monotherapy in Malignant Mesothelioma

By April 24, 2017No Comments

Condition

Malignant Mesothelioma

Estimated Enrollment: 29

Age Group: 18 Years and older   (Adult, Senior)

Gender: All

Study Type: Interventional

Study Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment

Study ID Numbers: MESOT-TREM-2008|2008-005171-95

Study First Received: July 18, 2012

Last Updated: July 20, 2012

Estimated Primary Completion Date: June 2012

 

Primary Outcome Measures:

Objective tumor response by modified Response Evaluation Criteria in Solid Tumor (RECIST)|Disease control rate|Progression free survival|Safety

Sponsors and Collaborators:

Azienda Ospedaliera Universitaria Senese

Website Link: https://ClinicalTrials.gov/show/NCT01649024

Leave a Reply